Clinical Trial Update: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm [Phase 1]

View source ↗

Summary

This document describes an ongoing Phase 1 clinical trial evaluating a genetically modified T-cell immunotherapy for adults with relapsed/refractory acute myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm

Snippet

Sponsor: City of Hope Medical Center | Conditions: Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING